Abstract:Objective To analyze the predictive value of baseline vitamin D level on the virological response of chronic hepatitis B.Methods A total of 115 inpatients with chronic hepatitis B from October 2017 to December 2019 in the Third People′s Hospital of Shenzhen were included.According to the hepatitis B virus DNA quantitative analysis at treatment week 24,patients were divided into HBV DNA-negative group and HBV DNA-positive group.The clinical baseline characteristics of the two groups were compared.Predictive models were established using multivariate Logistic regression analyses,with the receiver operating characteristic(ROC)curve and the Hosmer-Lemeshow goodness of fit test employed as the evaluation indicators.Results Antiviral treatment for 24 weeks,71 cases(61.74%)and 44 cases(38.26%)were HBV DNA-negative and HBV DNA-positive respectively.With lower HBV DNA level and higher vitamin D level,the 24-week virological outcomes were better(P<0.05).HBV DNA level and alanine aminotransferase were included in model 1,and HBV DNA level,HBsAg level,total bilirubin,and 25-hydroxy vitamin D were included in model 2.The areas under the ROC curve(AUC)of model 1 and model 2 were 0.735(95%CI:0.639-0.831)and 0.810(95%CI:0.732-0.890)respectively.The AUC of the two models was compared,and the difference was statistically significant(P=0.039).Conclusion The predictive model based on the baseline vitamin D level has a good predictive value for the 24-week virological response in the treatment of chronic hepatitis B.
李轩;张丽娜;王松;王方;何清. 维生素D水平对慢性乙型肝炎抗病毒疗效的预测价值[J]. 中国当代医药, 2021, 28(15): 12-15.
LI Xuan;ZHANG Li-na;WANG Song;WANG Fang;HE Qing. Predictive value of vitamin D level on antiviral efficacy of chronic hepatitis B. 中国当代医药, 2021, 28(15): 12-15.
Aziz M,Aziz H,Waheed Y,et al.Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients[J].Viral Immunol,2018,31(9):632-638.
[2]
Zeuzem S,Gane E,Liaw YF,et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol,2009,51(1):11-20.
[3]
Martens PJ,Gysemans C,Verstuyf A,et al.Vitamin D′s Effect on Immune Function[J].Nutrients,2020,12(5):1248.
[4]
Kim GA,Lim YS,Han S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut,2018,67(5):945-952.
[5]
Chang Y,Choe WH,Sinn DH,et al.Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus(HBV)e Antigen-Positive Chronic HBV Genotype C Infection:A Nationwide,Multicenter,Retrospective Study[J].J Infect Dis,2017,216(11):1407-1414.
Tang A,Hallouch O,Chernyak V,et al.Epidemiology of hepatocellular carcinoma:target population for surveillance and diagnosis[J].Abdom Radiol(NY),2018,43(1):13-25.
Cho JY,Sohn W,Sinn DH,et al.Long-term real-world entecavir therapy in treatment-nave hepatitis B patients:baseline hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response[J].Korean J Intern Med,2017,32(4):636-646.
Ye B,Liu X,Li X,et al.T-cell exhaustion in chronic hepatitis B infection:current knowledge and clinical significance[J].Cell Death Dis,2015,6(3):e1694.
[12]
Li TY,Yang Y,Zh ou G,et al.Immune suppression in chronic hepatitis B infection associated liver disease:A review[J].World J Gastroenterol,2019,25(27):3527-3537.
[13]
He LJ,Zhang HP,Li HJ,et al.Effect of Serum Vitamin D Levels on Cellular Immunity and Antiviral Effects in Chronic Hepatitis B Patients[J].Clin Lab,2016,62(10):1933-1939.
[15]
Gal-Tanamy M,Bachmetov L,Ravid A,et al.Vitamin D:an innate antiviral agent suppressing hepatitis C virus in human hepatocytes[J].Hepatology,2011,54(5):1570-1579.
[16]
Matsumura T,Kato T,Sugiyama N,et al.25-Hydroxyvitamin D3suppresses hepatitis C virus production[J].Hepatology,2012,56(4):1231-1239.
[17]
Bi Y,Zhang W,Sun J,et al.Therapeutic and immune function improvement of vitamin D combined with IFN-α on mouse with hepatitis B infection[J].Int J Immunopathol Pharmacol,2018,32:2058738418775250.
[18]
Sheppard-Law S,Zablotska-Manos I,Kermeen M,et al.Factors associated with non-adherence to HBV antiviral therapy[J].Antivir Ther,2018,23(5):425-433.